Skip to main content
SpringerLink
Log in

Orgotein (superoxide dismutase): A drug for the amelioration of radiation-induced side effects

A double-blind, placebo-controlled study in patients with bladder tumours

  • Published:
Urological Research Aims and scope Submit manuscript

Summary

Orgotein, the drug version of Cu-Zn superoxide dismutases is a new and safe anti-inflammatory agent. Animal experiments have shown that it does not interfere with the tumourolytic effects of radiation or chemotherapy. A double-blind, placebo-controlled study has demonstrated that orgotein injected after each daily irradiation session can be used safely and effectively to ameliorate or prevent the side effects due to high-energy radiation therapy (8,400 or 6,400 rads) of bladder tumours. Orgotein significantly reduced the signs and symptoms both in the bladder and the bowel, indicating that it provides a therapeutic regimen for control of these side effects, which to date could only be treated symptomatically.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fridovich, I.: Superoxide dismutases. Annual Review of Biochemistry 44, 147 (1975)

    Google Scholar 

  2. Carson, S., Vogin, E. E., Huber, W., Schulte, T. L.: Safety tests of orgotein, an antiinflammatory protein. Toxicology and Applied Pharmacology 26, 184 (1973)

    Google Scholar 

  3. Huber, W., Menander-Huber, K. B., Saifer, M. G. P., Dang, P. H.-C.: Studies on the clinical and laboratory pharmacology of drug formulations of bovine Cu-Zn superoxide dismutases (orgotein). In: Perspectives in inflammation. Willoughby, D. A., Giroud, J. P., Velo, G. P. (eds.), p. 527. Baltimore: University Park Press 1977

    Google Scholar 

  4. Salin, M. L., McCord, J. M.: Free radicals and inflammation. Protection of phagocytosing leukocytes by superoxide dismutase. Journal of Clinical Investigation 56, 1319 (1975)

    Google Scholar 

  5. Moss, W. T., Ackermann, L. V.: Therapeutic Radiology. 2nd Ed. St. Louis: Mosby 1965

    Google Scholar 

  6. Huber, W., Menander-Huber, K. B., Saifer, M. G. P.: Unpublished results

  7. Edsmyr, F., Huber, W., Menander, K. B.: Orgotein efficacy in ameliorating side effects due to radiation therapy. I. Double-blind, placebo-controlled trial in patients with bladder tumors. Current Therapeutic Research 19, 198 (1976)

    Google Scholar 

  8. Littbrand, B., Edsmyr, F., Révész, W.: A low dose fractionation scheme for the radiotherapy of carcinoma of the bladder. Bulletin du Cancer 62, 241 (1975)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Radiumhemmet, Karolinska Sjukhuset, Stockholm, Sweden

    K. B. Menander-Huber, F. Edsmyr & W. Huber

  2. Department of Urology, Karolinska Sjukhuset, Stockholm, Sweden

    K. B. Menander-Huber, F. Edsmyr & W. Huber

  3. Diagnostic Data, Inc., Mountain View, California, USA

    K. B. Menander-Huber, F. Edsmyr & W. Huber

Authors
  1. K. B. Menander-Huber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Edsmyr
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. Huber
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Menander-Huber, K.B., Edsmyr, F. & Huber, W. Orgotein (superoxide dismutase): A drug for the amelioration of radiation-induced side effects. Urol. Res. 6, 255–257 (1978). https://doi.org/10.1007/BF00262630

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00262630

Key words

Search

Navigation